Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2473436 | Current Opinion in Virology | 2011 | 12 Pages |
We compare the design, mechanism of action, and clinical efficacy of two recently licensed paradigm shifting vaccines. Zostavax is the first vaccine licensed to prevent disease in patients already infected with a pathogen, and is contrasted with Gardasil and Cervarix, the first vaccines designed and licensed specifically to prevent cancers.
► HPV vaccines are effective at preventing HPV related anogenital disease in men and women previously uninfected with HPV. ► Evidence of field efficacy of HPV vaccines is now available. ► As with most vaccines, induced antibody is of limited efficacy as a surrogate marker for protection. ► The herpes zoster vaccine is the first to prevent the consequences of reactivation of a latent infection. ► This vaccine prevents herpes zoster and often attenuates the disease when prevention fails. ► These beneficial effects of vaccination decline significantly at age 80 and greater.